ValveStrong will commercialize the first patient-specific hybrid heart valve prosthesis with self-regenerative capacity, lifelong durability, and complete biocompatibility. Since ValveStrong’s technology can be incorporated into both surgical and transcatheter valves, it has a competitive cost structure with the potential to capture a significant portion of the $3.5 billion current annual worldwide heart valve replacement market.